Company Overview of Vaccinex, Inc.
Vaccinex, Inc., a biotechnology company, engages in the discovery and development of human monoclonal antibodies. The company focuses on developing antibody treatments relevant to cancer, inflammation, and auto-immune diseases, as well as products for the treatment of oncology, multiple sclerosis oncology, hematological, breast cancer, and infectious diseases. Its ACTIVMAb antibody discovery technology enables the development of therapeutic antibodies, as well as provides fee-based antibody discovery and research services for client companies; and VX15/2503 humanized monoclonal antibody targets the multi-functional protein semaphorin 4D in patients with multiple sclerosis. The company was fo...
1895 Mount Hope Avenue
Rochester, NY 14620
Founded in 1997
Key Executives for Vaccinex, Inc.
Co-Founder, Chief Executive Officer, President and Director
Chief Operating Officer and Senior Vice President
Chief Scientific Officer and Senior Vice President of Research
Senior Vice President of Development
Compensation as of Fiscal Year 2014.
Vaccinex, Inc. Key Developments
Vaccinex, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 01:30 PM
Apr 6 15
Vaccinex, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 01:30 PM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: Maurice Zauderer, Co-Founder, Chief Executive Officer, President and Director.
Vaccinex, Inc. Provides an Update on its VX15/2503 Phase 1 Clinical Trial in Multiple Sclerosis Patients
Mar 31 15
Vaccinex, Inc. announced the successful completion of a multicenter phase 1, randomized, double-blind, placebo-controlled, single ascending-dose safety and tolerability study in adult patients with Multiple Sclerosis. A total of 50 patients were enrolled in 1 of 5 cohorts to determine the safety and tolerability of VX15/2503 when administered IV in a single dose. VX15/2503 is a monoclonal antibody discovered, characterized, and successfully tested by Vaccinex in preclinical models of Multiple Sclerosis and Huntington's Disease. VX15/2503 was found to be well tolerated at dose levels of up to 20 mg/kg with no reports of treatment-related serious adverse events. No maximum tolerated dose was determined and no dose-limiting toxicities were observed. Preliminary data suggests that the half-life of a single dose of antibody is 21 to 23 days at the 20 mg/kg dose level, and that saturation of the SEMA4D target receptor lasted for approximately 155 days. A phase 2 clinical trial of the VX15/2503 antibody in Huntington's Disease is planned to begin in the first half of 2015.
Vaccinex Signs Multi-Target Collaboration Deal with FPRX
Mar 19 15
Vaccinex announced it signed a multi-target collaboration deal with FPRX to discover monoclonal antibodies against novel targets identified by Five Prime's proprietary discovery platform. Under the terms of the agreement, FPRX will be granted exclusive, worldwide rights to develop and market monoclonal antibodies discovered by Vaccinex. Vaccinex will receive certain upfront fees, research support and performance payments as well as milestone payments and royalties on future sales of products commercialized by FPRX.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|